Travere Therapeutics Inc (TVTX)

$34.50 +0.61 (1.80%)
Market Cap 3.09B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,218,000
Avg Vol 2,305,142
Day's Range N/A - N/A
Shares Out 89.47M
Stochastic %K 61%
Beta 0.90
Analysts Strong Sell
Price Target $41.14

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
Meigs1865
Meigs1865 Nov. 13 at 9:19 PM
$TVTX Given the thumping across the market today, this is not that a big of a surprise. We are back to the prices on November 11th, 2 days ago. Hopefully, we will claw back some of the ground lost today, tomorrow.
0 · Reply
Meigs1865
Meigs1865 Nov. 11 at 5:55 PM
$TVTX Back up to where we were after the ER. One of the officers sold off $2M when it hit $36.00
0 · Reply
JFDI
JFDI Nov. 11 at 2:30 PM
$TVTX Base
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 11 at 11:44 AM
$TVTX Share Price: $34.39 Contract Selected: Mar 20, 2026 $35 Calls Buy Zone: $5.20 – $6.43 Target Zone: $9.50 – $11.61 Potential Upside: 72% ROI Time to Expiration: 128 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
Meigs1865
Meigs1865 Nov. 8 at 4:26 PM
$TVTX pull back this week has more to do with the overall market than TVTX fundamentals. TVTX is still ranked #9 on the IBD 50, O'Neil has observed that when the overall market goes down, 80% of the stocks follow the herd down regardless of fundamentals. The reverse is also true. This combined with TVTX hitting a 52 week high and investors taking profits within a market experiencing hysteria over the value of AI stocks, caused the 8% drop this week.
1 · Reply
Ruffy__
Ruffy__ Nov. 6 at 8:33 PM
$TVTX wow 🚀
0 · Reply
Meigs1865
Meigs1865 Nov. 6 at 7:05 PM
$TVTX good news that makes approval all but certain in January! https://www.businesswire.com/news/home/20251106843166/en/Travere-Therapeutics-Announces-Late-Breaking-Data-from-Phase-3-DUPLEX-Study-of-FILSPARI-in-FSGS-Presented-at-the-American-Society-of-Nephrology-ASN-Kidney-Week-2025
0 · Reply
Meigs1865
Meigs1865 Nov. 6 at 6:55 PM
$TVTX Interesting how all the markets indices are significantly in the Red and TVTX is holding rather steady. Any thoughts on this price stability while everyone else has their hair on fire? AI stock holders moving to healthcare, energy and pharma? Other thoughts?
1 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 5:45 PM
$TVTX News just posted on FSGS study. (Strange time of day to release news). Data is fantastic. Feel like FSGS approval is a slam dunk. $LLY and $NVS are likely watching very closely, if not already accumulating. Hope that kicks $AZN and $JNJ into higher gear on $TVTX
2 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:10 PM
$TVTX (Sorry, it forced me to separate the posts before it would accept).
0 · Reply
Latest News on TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:00 PM EST - 6 days ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

Nov 6, 2025, 11:00 AM EST - 10 days ago

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences

Nov 4, 2025, 5:23 PM EST - 12 days ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter

Oct 31, 2025, 7:55 AM EDT - 16 days ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter

ATEC

Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:26 PM EDT - 16 days ago

Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 4:01 PM EDT - 17 days ago

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Oct 23, 2025, 4:30 PM EDT - 24 days ago

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Oct 17, 2025, 9:01 AM EDT - 4 weeks ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

Sep 26, 2025, 7:00 AM EDT - 7 weeks ago

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 2 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX

Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Sep 12, 2025, 3:47 PM EDT - 2 months ago

Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval

Sep 10, 2025, 2:21 PM EDT - 2 months ago

Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

Sep 10, 2025, 7:01 AM EDT - 2 months ago

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 10:09 PM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 3:12 AM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

Sep 3, 2025, 7:01 AM EDT - 2 months ago

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

Travere Therapeutics, Inc. (TVTX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 6:17 PM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Presents At Citi's Biopharma Back To School Conference Transcript

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Aug 28, 2025, 12:40 PM EDT - 2 months ago

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

Aug 27, 2025, 5:09 PM EDT - 2 months ago

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Aug 12, 2025, 12:15 PM EDT - 3 months ago

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:41 PM EDT - 3 months ago

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

Travere Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 3 months ago

Travere Therapeutics Reports Second Quarter 2025 Financial Results

Travere Therapeutics to Report Second Quarter 2025 Financial Results

Jul 30, 2025, 4:30 PM EDT - 3 months ago

Travere Therapeutics to Report Second Quarter 2025 Financial Results

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Jun 11, 2025, 7:01 AM EDT - 5 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Jun 10, 2025, 7:00 AM EDT - 5 months ago

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 4, 2025, 10:00 AM EDT - 5 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Jun 3, 2025, 4:30 PM EDT - 5 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Jun 2, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

Jun 1, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 6 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

May 28, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

May 23, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

May 21, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

May 20, 2025, 5:45 PM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

Travere Therapeutics: Establishing A Position After Last Week's Selloff

May 20, 2025, 3:47 PM EDT - 6 months ago

Travere Therapeutics: Establishing A Position After Last Week's Selloff

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 15, 2025, 4:05 PM EDT - 6 months ago

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:07 PM EDT - 7 months ago

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

Travere Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 7 months ago

Travere Therapeutics Reports First Quarter 2025 Financial Results

Meigs1865
Meigs1865 Nov. 13 at 9:19 PM
$TVTX Given the thumping across the market today, this is not that a big of a surprise. We are back to the prices on November 11th, 2 days ago. Hopefully, we will claw back some of the ground lost today, tomorrow.
0 · Reply
Meigs1865
Meigs1865 Nov. 11 at 5:55 PM
$TVTX Back up to where we were after the ER. One of the officers sold off $2M when it hit $36.00
0 · Reply
JFDI
JFDI Nov. 11 at 2:30 PM
$TVTX Base
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 11 at 11:44 AM
$TVTX Share Price: $34.39 Contract Selected: Mar 20, 2026 $35 Calls Buy Zone: $5.20 – $6.43 Target Zone: $9.50 – $11.61 Potential Upside: 72% ROI Time to Expiration: 128 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
Meigs1865
Meigs1865 Nov. 8 at 4:26 PM
$TVTX pull back this week has more to do with the overall market than TVTX fundamentals. TVTX is still ranked #9 on the IBD 50, O'Neil has observed that when the overall market goes down, 80% of the stocks follow the herd down regardless of fundamentals. The reverse is also true. This combined with TVTX hitting a 52 week high and investors taking profits within a market experiencing hysteria over the value of AI stocks, caused the 8% drop this week.
1 · Reply
Ruffy__
Ruffy__ Nov. 6 at 8:33 PM
$TVTX wow 🚀
0 · Reply
Meigs1865
Meigs1865 Nov. 6 at 7:05 PM
$TVTX good news that makes approval all but certain in January! https://www.businesswire.com/news/home/20251106843166/en/Travere-Therapeutics-Announces-Late-Breaking-Data-from-Phase-3-DUPLEX-Study-of-FILSPARI-in-FSGS-Presented-at-the-American-Society-of-Nephrology-ASN-Kidney-Week-2025
0 · Reply
Meigs1865
Meigs1865 Nov. 6 at 6:55 PM
$TVTX Interesting how all the markets indices are significantly in the Red and TVTX is holding rather steady. Any thoughts on this price stability while everyone else has their hair on fire? AI stock holders moving to healthcare, energy and pharma? Other thoughts?
1 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 5:45 PM
$TVTX News just posted on FSGS study. (Strange time of day to release news). Data is fantastic. Feel like FSGS approval is a slam dunk. $LLY and $NVS are likely watching very closely, if not already accumulating. Hope that kicks $AZN and $JNJ into higher gear on $TVTX
2 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:10 PM
$TVTX (Sorry, it forced me to separate the posts before it would accept).
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:09 PM
$TVTX Then, in Feb, $NVS or $LLY announce acquisition, in the $60.00 to $75.00 range (with $AZN and $JNJ watching )
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:07 PM
$TVTX I expect it to trade sideways for a week, then begin an orderly climb to $45.00 Then in Jan, PDUFA approval jumps it to $55.00
2 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:05 PM
$TVTX on the $LGND earnings call this morning (which were spectacular), it was mentioned FSGS sales will exceed IgAN sales.
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:04 PM
$TVTX why won’t it let me post?
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 3:59 PM
$TVTX test
0 · Reply
Smellmahass
Smellmahass Nov. 5 at 5:08 AM
$BHVNSO adcoms gets cancelled aa bew fda dont want it approved. How do this go about $TVTX
0 · Reply
DARKP00L
DARKP00L Nov. 4 at 4:37 PM
$TVTX 11:35 on Nov. 04 2025 Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $35 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 4:35 PM
Piper Sandler has adjusted their stance on Travere Therapeutics ( $TVTX ), setting the rating to Neutral with a target price of 26 → 35.
0 · Reply
Drashkawisha
Drashkawisha Nov. 3 at 3:48 PM
$TVTX pulling back after beating earnings last week? And now the whole market is red? This is a gift. Already profitable, FILSPARI sales are growing strong, and they have the FSGS expansion PDUFA in Jan. Thank you for the discount.
0 · Reply
JFais
JFais Nov. 2 at 10:55 PM
$IOVA $TVTX
2 · Reply
JFais
JFais Nov. 2 at 9:43 PM
$IOVA $TVTX- one of my worst swaps of all time 🤦‍♂️
2 · Reply